EEF2 eukaryotic translation elongation factor 2
ENSG00000167658 · protein coding · Open Targets profile
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation (PubMed:26593721). During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl- tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively (PubMed:26593721). Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome (PubMed:26593721). .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- GO CC high conf
- PROTAC
- UniProt Ubiquitination, Database Ubiquitination, Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.2462799996137619 (upper bound 0.35464000701904297). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 32 registry trials, updated in the last three years, of the most advanced drugs against EEF2 (oportuzumab monatox, tagraxofusp, denileukin diftitox, cintredekin besudotox, resimmune, LMB-100, LMB-2), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Robert J KreitmanNational Cancer Institute (NCI) · 2 of 2 trials Phase 2+
- Alexander OlawaiyeUPMC Hillman Cancer Center · 1 of 1 trials Phase 2+
- Azam GhafoorNational Cancer Institute (NCI) · 1 of 1 trials Phase 2+
- Guillermo M BravoM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Naveen PemmarajuM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Nicholas ShortM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Qaiser BashirM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Abdulraheem YacoubUniversity of Kansas Medical Center · 0 of 1 trials Phase 2+
- Adam LambleSeattle Children's Hospital · 0 of 1 trials Phase 2+
- Alexander AmbinderSKCCC Johns Hopkins Medical Institution · 0 of 1 trials Phase 2+
- Andrew LaneDana-Farber Cancer Institute · 0 of 1 trials Phase 2+
- Caspian OliaiUCLA / Jonsson Comprehensive Cancer Center · 0 of 1 trials Phase 2+
- David S SchrumpNational Cancer Institute (NCI) · 0 of 1 trials Phase 2+
- Monzr M. Z Al MalkiCity of Hope Medical Center · 0 of 1 trials Phase 2+
- Raffit HassanNational Cancer Institute (NCI) · 0 of 1 trials Phase 2+
Registry trials of oportuzumab monatox, tagraxofusp, denileukin diftitox, cintredekin besudotox, resimmune, LMB-100, LMB-2 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 26 of 31 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
32 trials of drugs against EEF2 were stopped early; 6 give no reason
Terminated, withdrawn and suspended interventional trials of oportuzumab monatox, tagraxofusp, denileukin diftitox, cintredekin besudotox, resimmune, LMB-100, LMB-2, LMB-7, LMB-9, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 32.
- terminated · 2026-06-25 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs“Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML”
- withdrawn · 2026-05-18 · Virogen Biotechnology Inc. · matched by the registry's drug synonyms“This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to Virogen, the study was redesigned. This protocol will never start. The new protocol is NCT07529405.”
- terminated · 2025-08-11 · M.D. Anderson Cancer Center · Tagraxofusp-erzs“The study was terminated early due to slow enrollment.”
- terminated · 2025-01-30 · Gruppo Italiano Malattie EMatologiche dell'Adulto · tagraxofusp“poor enrollment”
- terminated · 2024-10-17 · Stemline Therapeutics, Inc. · Tagraxofusp-erzsNo reason given
- terminated · 2024-07-31 · M.D. Anderson Cancer Center · Tagraxofusp-erzs“The protocol was terminated early due to slow participant accrual and the sponsor not willing to provide the study drug.”
- terminated · 2024-04-17 · Stemline Therapeutics, Inc. · matched by the registry's drug synonymsNo reason given
- terminated · 2024-04-16 · National Cancer Institute (NCI) · LMB-100“Study was terminated due to slow accrual.”
- withdrawn · 2024-03-08 · Jonsson Comprehensive Cancer Center · Tagraxofusp-erzs“trial was not opened”
- terminated · 2024-02-02 · National Cancer Institute (NCI) · LMB-100“Study was closed early due to slow accrual.”
- withdrawn · 2024-02-02 · National Cancer Institute (NCI) · LMB-100“No participants enrolled.”
- terminated · 2022-11-15 · Fred Hutchinson Cancer Center · denileukin diftitox“ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be supporting clinical trials that utilize this drug.”
- terminated · 2021-12-02 · National Cancer Institute (NCI) · LMB-100“Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).”
- terminated · 2021-10-25 · University of Louisville · matched by the registry's drug synonyms“low enrollment r/t requirement of prior treatment with denileukin diftitox”
- terminated · 2021-01-26 · University of Chicago · matched by the registry's drug synonyms“The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox.”
- terminated · 2020-04-27 · University of California, San Francisco · Denileukin diftitox“Manufacturing shortage of both Diftitox and Doxil”
- terminated · 2019-11-22 · National Cancer Institute (NCI) · LMB-100“Due to fatal occurrence (pneumonitis) attributed to one of the study drugs.”
- terminated · 2019-11-19 · National Cancer Institute (NCI) · Denileukin diftitox (Ontak)“Premature closure as study drug is no longer available from the manufacturer.”
- terminated · 2018-07-05 · National Institute of Neurological Disorders and Stroke (NINDS) · matched by the registry's drug synonymsNo reason given
- terminated · 2018-04-10 · The University of Texas Health Science Center at San Antonio · Denileukin Diftitox/SC Pegylated IFNα-2a“Lack of funding”
- terminated · 2017-12-28 · Masonic Cancer Center, University of Minnesota · Denileukin diftitox“study drug (Ontak) no longer available”
- terminated · 2017-06-20 · Barbara Ann Karmanos Cancer Institute · Denileukin Diftitox (Ontak)“Drug unavailable”
- withdrawn · 2016-12-15 · University of Miami · denileukin diftitoxNo reason given
- terminated · 2016-11-23 · Virogen Biotechnology Inc. · A-dmDT390-bisFv(UCHT1) (Resimmune®)“Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)”
- terminated · 2016-09-29 · Loyola University · matched by the registry's drug synonyms“Collaborator withdrew support due to a drug supply interruption.”
Paediatric incentives and obligations for EEF2's drugs
For oportuzumab monatox, tagraxofusp, denileukin diftitox, cintredekin besudotox, resimmune, LMB-100, LMB-2, LMB-7, LMB-9: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · EEF2 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002797-PIP01-20 (oportuzumab monatox, Treatment of urothelial carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 12 Aug 2020Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002797-PIP01-20, 2026-11-11
- EU orphan designation: yes · EU/3/01/075 positive 11 Dec 2001: Treatment of cutaneous T-cell lymphoma; EU/3/15/1567 positive 11 Nov 2015: Treatment of blastic plasmacytoid dendritic cell neoplasmRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Elzonris: authorised since 7 Jan 2021, orphan medicine, exceptional circumstances; Oportuzumab monatox DLRC Pharma Services: application withdrawnRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Tagraxofusp-erzs [Elzonris], 21 Dec 2018: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and olderRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 14 interventional studies of oportuzumab monatox, tagraxofusp, denileukin diftitox, cintredekin besudotox, resimmune, lmb-100, lmb-2, lmb-7, lmb-9 include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 10 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.